ライフサイエンスコーパス: mofetil

1 then steroids, tacrolimus, and mycophenolate mofetil.

2 ssion (IS) with tacrolimus and mycophenolate mofetil.

3 ized to methotrexate and 39 to mycophenolate mofetil.

4 ents receiving methotrexate or mycophenolate mofetil.

5 urin inhibitors, steroids, and mycophenolate mofetil.

6 of rapamycin, tacrolimus, and mycophenolate mofetil.

7 , male sex, and treatment with mycophenolate mofetil.

8 g of tacrolimus, steroids, and mycophenolate mofetil.

9 munosuppression with FK506 and mycophenolate mofetil.

10 dogs received cyclosporine and mycophenolate mofetil.

11 duction and were maintained on mycophenolate mofetil.

12 ion regimens of tacrolimus and mycophenolate mofetil.

13 lophosphamide, tacrolimus, and mycophenolate mofetil.

14 persisted after treatment with mycophenolate mofetil.

15 n, tacrolimus, prednisone, and mycophenolate mofetil.

16 of the immunosuppressant drug mycophenolate mofetil.

17 ts given cyclophosphamide than mycophenolate mofetil.

18 be blocked by the presence of mycophenolate mofetil.

19 34], P = 0.01), treatment with mycophenolate mofetil (0.68 [0.47-0.97], P = 0.03).

20 2.34], p=0.01), treatment with mycophenolate mofetil (0.68 [0.47-0.97], p= 0.03).

21 and GVHD immunoprophylaxis of mycophenolate mofetil (1 g three times a day, days 0-28) and tacrolimu

22 trexate, 25 mg weekly, or oral mycophenolate mofetil, 1 g twice daily, and were followed up monthly f

23 Tacrolimus, 4 mg/d, and mycophenolate mofetil, 1.0 g/d, versus intravenous cyclophosphamide wi

24 /d, tapered over 6 months, and mycophenolate mofetil, 1000 mg twice daily, for a mean of 24.3 months.

25 rradiation, cyclosporine A and mycophenolate mofetil (12 doses), and antilymphocyte serum (one dose);

26 4 after transplantation, oral mycophenolate mofetil 15 mg/kg per dose (maximum 1 g) every 8 h on day

27 , sirolimus 8 to 12 ng/mL with mycophenolate mofetil 2 g two times per day.

28 , phase 3 study comparing oral mycophenolate mofetil (2 g per day) and oral azathioprine (2 mg per ki

29 immunosuppression consisted of mycophenolate mofetil (28 days) and cyclosporine (35 days).

30 5 mg weekly (n = 107), or oral mycophenolate mofetil, 3 g daily (n = 109).

31 nagement Study (ALMS) trial of mycophenolate mofetil, 3) the Lupus Nephritis Assessment with Rituxima

32 ized to methotrexate and 16 to mycophenolate mofetil; 30 had acute VKH.

33 er with azathioprine than with mycophenolate mofetil (39.6% vs. 25.2%, P = 0.02).

34 and an antimetabolite, mostly mycophenolate mofetil (91.7%).

35 6, 9.8; P = .20) the odds with mycophenolate mofetil, a difference that was not statistically signifi

36 A) is the active metabolite of mycophenolate mofetil, a drug that is widely used for immunosuppressio

37 al [CI] 2.03-6.39), Neoral and mycophenolate mofetil (AHR 2.09, CI 1.31-3.31), and sirolimus and myco

38 1.31-3.31), and sirolimus and mycophenolate mofetil (AHR 2.77, CI 1.40-5.47), were associated with d

39 treated with cyclosporine and mycophenolate mofetil alone.

40 ed mycophenolate sodium versus mycophenolate mofetil along with reduced maintenance tacrolimus dosing

41 A) is the active metabolite of mycophenolate mofetil, an effective immunosuppressive drug.

42 lease tacrolimus, basiliximab, mycophenolate mofetil and 1 bolus of intraoperative corticosteroids (0

43 (11%) patients died (five [7%] mycophenolate mofetil and 11 [15%] cyclophosphamide), with most due to

44 maintenance treatment (116 to mycophenolate mofetil and 111 to azathioprine).

45 ing immunosuppression included mycophenolate mofetil and a calcineurin inhibitor.

46 , followed by maintenance with mycophenolate mofetil and an intensively dosed alphaCD40 (2C10R4) anti

47 Large controlled trials using mycophenolate mofetil and azathioprine for maintenance therapy have be

48 ional immunomodulators such as mycophenolate mofetil and biologics such as rituximab are effective in

49 er day (Arm 3; n=304) all with mycophenolate mofetil and corticosteroids (tapered) over 24 weeks, or

50 acebo, both on a background of mycophenolate mofetil and corticosteroids.

51 posure cyclosporine, both with mycophenolate mofetil and corticosteroids; 95/115 randomized patients

52 oved significantly in both the mycophenolate mofetil and cyclophosphamide groups.

53 or placebo, on a background of mycophenolate mofetil and glucocorticoids.

54 ents received cyclosporine and mycophenolate mofetil and gradually tapered prednisone.

55 urvivals after introduction of mycophenolate mofetil and induction with basiliximab.

56 difference in efficacy between mycophenolate mofetil and intravenous cyclophosphamide in ameliorating

57 were successfully weaned from mycophenolate mofetil and maintained on tacrolimus monotherapy.

58 osuppressive substance in both mycophenolate mofetil and mycophenolate sodium, and it is widely used

59 suggest that a combination of mycophenolate mofetil and prednisone may be an effective treatment for

60 ATG, mycophenolate sodium, or mycophenolate mofetil and rapid withdrawal of steroids.

61 ground of negative trials with mycophenolate mofetil and rituximab, there are recent data demonstrati

62 o oral steroids can be used in mycophenolate mofetil and rituximab-based regimes.

63 ALPS-specific toxicities, and mycophenolate mofetil and sirolimus have been demonstrated to have mar

64 50% reduction in doses of both mycophenolate mofetil and Tac without antiviral therapy.

65 nosuppression with maintenance mycophenolate mofetil and tacrolimus between October 2008 and January

66 dase-deficient F344 rats using mycophenolate mofetil and tacrolimus for partial lymphocyte-directed i

67 ll-depleting agent followed by mycophenolate mofetil and tacrolimus is presently the most frequently

68 Mycophenolate mofetil and TNF-alpha antagonists can be used in case of

69 tients received tacrolimus and mycophenolate mofetil and underwent a 5-day glucocorticoid taper in a

70 rexate or 1 g twice daily oral mycophenolate mofetil and were monitored monthly for 6 months.

71 ) dose or conversion to either mycophenolate mofetil and/or rapamycin resulted in variable results an

72 ompared with use of tacrolimus/mycophenolate mofetil) and following a diagnosis of cutaneous squamous

73 s disease including Rituximab, mycophenolate mofetil, and adrenocorticotropic hormone, with an emphas

74 maintenance therapy (steroids, mycophenolate mofetil, and calcineurin inhibitor).

75 ed of basiliximab, tacrolimus, mycophenolate mofetil, and corticosteroids in 80% of patients, whereas

76 n combination with tacrolimus, mycophenolate mofetil, and corticosteroids.

77 eceived basiliximab induction, mycophenolate mofetil, and corticosteroids.

78 ssociating standard-dose CNIs, mycophenolate mofetil, and corticosteroids.

79 nance therapy with tacrolimus, mycophenolate mofetil, and corticosteroids.

80 RDP using thymoglobulin, mycophenolate mofetil, and CsA in selected pediatric KTx recipients is

81 ff over 6 days, thymoglobulin, mycophenolate mofetil, and cyclosporine A (CsA).

82 ation consisted of tacrolimus, mycophenolate mofetil, and glucocorticoids.

83 yclophosphamide, azathioprine, mycophenolate mofetil, and methotrexate.

84 istributed among azathioprine, mycophenolate mofetil, and methotrexate.

85 received cyclophosphamide and mycophenolate mofetil, and more children with JIA received interleukin

86 dom block sizes to tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide (cycl

87 Tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide was t

88 0.94; p=0.044) for tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide, 0.98

89 ical (77 [84%] for tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide; 73 [

90 d maraviroc; 92 to tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide; and

91 rade 4 events with tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide; ten

92 me consisting of cyclosporine, mycophenolate mofetil, and prednisolone were well tolerated and equall

93 mus combined with basiliximab, mycophenolate mofetil, and prednisolone.

94 ethylprednisolone, tacrolimus, mycophenolate mofetil, and prednisone were commenced.

95 hymocyte globulin, tacrolimus, mycophenolate mofetil, and prednisone.

96 e combination of cyclosporine, mycophenolate mofetil, and sirolimus has become the new standard GVHD

97 ination regimen (cyclosporine, mycophenolate mofetil, and sirolimus).

98 ylaxis comprised cyclosporine, mycophenolate mofetil, and sirolimus.

99 lobulin induction, tacrolimus, mycophenolate mofetil, and steroid withdrawal by day 5 after transplan

100 followed by de novo sirolimus, mycophenolate mofetil, and steroids were compared; group 1: 204 patien

101 n combination with tacrolimus, mycophenolate mofetil, and steroids.

102 nosuppression with tacrolimus, mycophenolate mofetil, and steroids.

103 obulin, calcineurin inhibitor, mycophenolate mofetil, and steroids.

104 ntibody followed by sirolimus, mycophenolate mofetil, and steroids.

105 on high-dose cyclophosphamide, mycophenolate mofetil, and tacrolimus or sirolimus.

106 plete allografting, then PTCy, mycophenolate mofetil, and tacrolimus.

107 basiliximab, tapered steroids, mycophenolate mofetil, and tacrolimus.

108 ppression was with prednisone, mycophenolate mofetil, and tacrolimus.

109 oups consisting of prednisone, mycophenolate mofetil, and tacrolimus.

110 Methotrexate and mycophenolate mofetil are commonly used immunomodulatory therapies for

111 Both MPA and mycophenolate mofetil are highly specific inhibitors of guanine nucleo

112 Calcineurin inhibitors and mycophenolate mofetil are potential salvage therapies, and reagents su

113 pression with cyclosporine and mycophenolate mofetil as a control group, we compared outcomes with ex

114 Clinical trials evaluating mycophenolate mofetil as remission induction therapy, gusperimus, beli

115 Mycophenolate mofetil at intensified and individually adjusted dose in

116 ed mycophenolate sodium versus mycophenolate mofetil at month 6 among African Americans and at month

117 KTRs maintained on tacrolimus/mycophenolate mofetil-based regimen along with steroid.

118 imus QD 0.2 mg/kg per day with mycophenolate mofetil, basiliximab, and corticosteroids given only per

119 and the present preference for mycophenolate mofetil because of its better tolerability and toxicity

120 alcineurin inhibitor (CNI) and mycophenolate mofetil by 30% to 50% (n=23), or we switched from CNI to

121 ression regimes (azathioprine, mycophenolate mofetil, calcineurin inhibitors, mammalian target of rap

122 with IFN-beta-1a (Avonex) and mycophenolate mofetil (Cellcept) modulated the hyperphosphorylation of

123 induction with tacrolimus and mycophenolate mofetil combination maintenance, both regimens using ste

124 infectious uveitis, the use of mycophenolate mofetil compared with methotrexate as first-line cortico

125 patients (35 methotrexate, 32 mycophenolate mofetil) contributed to the primary outcome.

126 essive regimen, when used with mycophenolate mofetil, corticosteroids, and anti-interleukin-2 recepto

127 regimen, including sirolimus, mycophenolate mofetil, corticosteroids, and anti-interleukin-2 recepto

128 monly used in combination with mycophenolate mofetil, CsA, or TAC.

129 late mofetil versus tacrolimus+mycophenolate mofetil de novo, and (d) conversion from CNI to SRL vers

130 ia responses to cyclosporin or mycophenolate mofetil/dexamethasone.

131 Mycophenolate mofetil did not provide mycophenolic acid absorption as

132 Mycophenolate mofetil dose reduction was independently associated with

133 In the triple-drug group, mycophenolate mofetil doses were the same as in the standard group, bu

134 or more than 2000 mg per day (mycophenolate mofetil equivalents) was significantly higher with enter

135 Tacrolimus or sirolimus and mycophenolate mofetil exposure was identical between groups.

136 interstitial lung disease with mycophenolate mofetil for 2 years or cyclophosphamide for 1 year both

137 s of both cyclophosphamide and mycophenolate mofetil for progressive scleroderma-related interstitial

138 titis C virus reinfection, and mycophenolate mofetil-free regimens were significant risk factors for

139 lapses were more common in the mycophenolate mofetil group (42/76 patients) compared with the azathio

140 ne to 24 months by 2.19 in the mycophenolate mofetil group (95% CI 0.53-3.84) and 2.88 in the cycloph

141 ts in 8 patients (7.5%) in the mycophenolate mofetil group (HR, 0.53 [95% CI, 0.23-1.18]; P = .12).

142 p and in 23.5% of those in the mycophenolate mofetil group (P = 0.11), and the rate of withdrawal due

143 4% (19 of 116 patients) in the mycophenolate mofetil group and 32.4% (36 of 111) in the azathioprine

144 plant recipients receiving 2 g mycophenolate mofetil (group A, n=75) versus 1.440 g enteric-coated my

145 Mycophenolate mofetil has emerged as a viable alternative to cyclophos

146 Mycophenolate mofetil has not become the "wonder drug" that had been a

147 0.62; 95% CI, 0.15-2.53), and mycophenolate mofetil hydrochloride (OR, 0.66; 95% CI, 0.21-2.03) had

148 pheresis, rituximab, sirolimus, mycofenolate mofetil, imatinib, pentostatin and infusion of mesenchym

149 ing regimen with sirolimus and mycophenolate mofetil immune suppression.

150 ort course of cyclosporine and mycophenolate mofetil immunosuppression.

151 e tacrolimus, basiliximab, and mycophenolate mofetil immunosuppressive regimen is efficacious, with a

152 mprovers were downregulated in mycophenolate mofetil improvers, suggesting that immunomodulatory or c

153 rituximab with azathioprine or mycophenolate mofetil improves the high-resolution computed tomography

154 We compared Everolimus versus mycophenolate mofetil in an investigator-initiated single-center trial

155 observed in patients receiving mycophenolate mofetil in any treatment combination (HR 0.80, P=0.438 f

156 a demonstrating superiority of mycophenolate mofetil in certain subgroups.

157 ts of the use of rituximab and mycophenolate mofetil in resistant disease.

158 Mycophenolate mofetil is a potent immunosuppressant medication approve

159 est that the immunosuppressant mycophenolate mofetil is associated with anemia.

160 lin induction, tacrolimus, and mycophenolate mofetil is associated with excellent patient and kidney

161 al lung disease (ILD), whereas mycophenolate mofetil is effective in both polymyositis and refractory

162 ), to test the hypothesis that mycophenolate mofetil is more effective than azathioprine for preventi

163 Mycophenolate mofetil is, therefore, a suitable alternative to cycloph

164 py, often with azathioprine or mycophenolate mofetil, is required to consolidate remission and preven

165 rine, thalidomide analogs, and Mycophenalate Mofetil may also be effective in refractory CLE.

166 Immunosuppression included mycophenolate mofetil (MMF) (2 g/day), tacrolimus (target trough 4-8 n

167 reduced-dose cyclosporine, or mycophenolate mofetil (MMF) 3 g/day with standard-dose cyclosporine (p

168 Mycophenolate mofetil (MMF) and combination therapies including MMF, a

169 Prophylactic drugs, such as mycophenolate mofetil (MMF) and cyclosporine A (CsA), are often used t

170 s initially maintained on Tac, mycophenalate mofetil (MMF) and prednisone.

171 ) or cyclosporine A (CsA) with mycophenolate mofetil (MMF) and steroids after heart transplantation (

172 imus (Tac) in combination with mycophenolate mofetil (MMF) and those maintained on a regimen of Tac a

173 enolate sodium (EC-MPS) versus mycophenolate mofetil (MMF) and to examine the impact of dose manipula

174 Nowadays, tacrolimus (Tac) and mycophenolate mofetil (MMF) are considered more efficient than cyclosp

175 sing T- and B-cell markers and mycophenolate mofetil (MMF) dosage.

176 oid withdrawal, tacrolimus and mycophenolate mofetil (MMF) for 1 month followed by randomization to s

177 tion to cyclosporine (CSP) and mycophenolate mofetil (MMF) for graft-versus-host disease (GVHD) proph

178 nicians are increasingly using mycophenolate mofetil (MMF) for the treatment of systemic lupus erythe

179 mus (Tac) and dose-intensified mycophenolate mofetil (MMF) further adjusted individually.

180 nhibitor (CNI) withdrawal with mycophenolate mofetil (MMF) has not become routine practice, due to co

181 Rapamycin and mycophenolate mofetil (MMF) have been used for maintenance immunosuppr

182 ermine whether the addition of mycophenolate mofetil (MMF) improves the efficacy of initial systemic

183 favorable long-term effects of mycophenolate mofetil (MMF) in renal transplantation, its introduction

184 aracterize dose adjustments of mycophenolate mofetil (MMF) in this setting.

185 study of daclizumab (DZB) and mycophenolate mofetil (MMF) including DZB(+)MMF(+), DZB(-)MMF(+), DZB(

186 and adverse effects caused by mycophenolate mofetil (MMF) inhibition may be genetically determined,

187 Mycophenolate mofetil (MMF) is an alternative to cyclophosphamide for

188 Mycophenolate mofetil (MMF) is an immunosuppressive agent (IS) which i

189 The use of mycophenolate mofetil (MMF) is associated with less acute rejection th

190 The prodrug ester mycophenolate mofetil (MMF) is frequently used in solid-organ and stem

191 enolate sodium (EC-MPS) versus mycophenolate mofetil (MMF) maintenance immunosuppression at the time

192 nt studies have suggested that mycophenolate mofetil (MMF) may offer advantages over intravenous cycl

193 day 28 posttransplantation to mycophenolate mofetil (MMF) or Everolimus combined with cyclosporine A

194 , was designed to test whether mycophenolate mofetil (MMF) plus corticosteroids was superior to corti

195 Mycophenolate mofetil (MMF) side effects often prompt dose reduction o

196 induction with tacrolimus and mycophenolate mofetil (MMF) therapy in renal transplantation, we analy

197 onstrated that conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC

198 core (MRSS) improvement during mycophenolate mofetil (MMF) treatment.

199 ess the effects of late CNI or mycophenolate mofetil (MMF) withdrawal on ambulatory blood pressure mo

200 ned the effects of late CNI or mycophenolate mofetil (MMF) withdrawal on echocardiographic parameters

201 dosing with tacrolimus (TAC), mycophenolate mofetil (MMF), and corticosteroids.

202 crolimus/sirolimus, tacrolimus/mycophenolate mofetil (MMF), and cyclosporine/sirolimus.

203 sociation of tacrolimus (TAC), mycophenolate mofetil (MMF), and prednisone with BKN in renal allograf

204 the combination of tacrolimus, mycophenolate mofetil (MMF), and steroids.

205 ts were initially treated with mycophenolate mofetil (MMF), cyclosporine A (CsA), and prednisone (pre

206 omparing early CW (tacrolimus, mycophenolate mofetil (MMF), daclizumab, and corticosteroids until day

207 mg/kg per day plus etanercept, mycophenolate mofetil (MMF), denileukin diftitox (denileukin), or pent

208 h either methotrexate (MTX) or mycophenolate mofetil (MMF).

209 ted with the immunosuppressant mycophenolate mofetil (MMF).

210 with both corticosteroids and mycophenolate mofetil (MMF).

211 combination of tacrolimus and mycophenolate mofetil (MMF).

212 or EC-MPS were comparable with mycophenolate mofetil (MMF).

213 cineurin inhibitor as follows: mycophenolate mofetil (MMF)/mycophenolate sodium+tacrolimus (TAC), MMF

214 us (FK-506, 0.1 mg/kg per day)/mycophenolate mofetil (MMF, 60 mg/kg per day), and anti-CD3 (50 mug/da

215 s (FK506; 0.1-0.5-1 mg/kg ip), mycophenolate mofetil (MMF; 60-120-300 mg/kg oral) or vehicle for 14 d

216 ety of a 1-year treatment with mycophenolate mofetil (MMF; target plasma mycophenolic acid trough lev

217 ne, pyrazofurin [PF], AVN-944, mycophenolate mofetil [MMF], and mycophenolic acid [MPA]), but not oba

218 Prednisolone, tacrolimus, and mycophenolate mofetil modified fecal microbiota at the family level in

219 s (n = 5), bortezomib (n = 3), mycophenolate mofetil (n = 2), splenectomy (n = 2), and second HCT (n

220 ed to azathioprine (n = 80) or mycophenolate mofetil (n = 76) and were followed up for a median of 39

221 re randomly assigned to either mycophenolate mofetil (n=69) or cyclophosphamide (n=73).

222 126 patients (mycophenolate mofetil [n=63] and cyclophosphamide [n=63]) with accepta

223 adjusted hazard ratio (HR) for mycophenolate mofetil of 1.69 (95% confidence interval [CI], 1.06-2.70

224 The effect of sirolimus or mycophenolate mofetil on NK cells was minimal.

225 MPA), the active metabolite of mycophenolate mofetil, on erythropoiesis in vitro.

226 essive therapy, typically with mycophenolate mofetil or cyclophosphamide and with glucocorticoids, al

227 ystemic immunosuppression with mycophenolate mofetil or cyclosporine A.

228 gastrointestinal symptoms with mycophenolate mofetil or EC-MPS in combination with Tac and cyclospori

229 ed after treatment with either mycophenolate mofetil or intravenous cyclophosphamide.

230 ance regimen of tacrolimus and mycophenolate mofetil or mycophenolate sodium was associated with 25%

231 he regimen of cyclosporine and mycophenolate mofetil or mycophenolate sodium.

232 Whether treatments such as mycophenolate mofetil or statins have a role in prevention of lupus CV

233 axis regimen (cyclosporine and mycophenolate mofetil) or the triple-drug combination regimen (cyclosp

234 with methotrexate and 47% with mycophenolate mofetil (P = 0.09).

235 mean tacrolimus (P=0.0009) and mycophenolate mofetil (P=0.01) blood levels.

236 ds, cyclophosphamide, dapsone, mycophenolate mofetil, plasmapheresis, colchicine, hydroxychloroquine,

237 globulin induction followed by mycophenolate mofetil plus calcineurin inhibitors (n=28, with 7 also r

238 ce therapy with belatacept and mycophenolate mofetil plus induction with basiliximab and LFA-1 blocka

239 raft function for >=2 years on mycophenolate mofetil plus prednisone.

240 e randomized to cyclosporin or mycophenolate mofetil plus pulse oral dexamethasone with a primary out

241 protocol included tacrolimus, mycophenolate mofetil, prednisone, and antithymocyte globulins.

242 ment that included tacrolimus, mycophenolate mofetil, prednisone, and, for induction, antithymocyte g

243 d with biopsy and treated with mycophenolate mofetil presented with a 2-day history of progressively

244 sitioning to azathioprine from mycophenolate mofetil prior to pregnancy in patients with quiet lupus

245 the standard cyclosporine and mycophenolate mofetil prophylaxis therapy for preventing acute GVHD in

246 ontrolled trial, International Mycophenolate Mofetil Protocol to Reduce Outbreaks of Vasculitides (IM

247 The Tricontinental Mycophenolate Mofetil Renal Transplantation Study was a double-blind r

248 sirolimus to cyclosporine and mycophenolate mofetil resulted in a lower incidence of acute GVHD, thu

249 sirolimus to cyclosporine and mycophenolate mofetil resulted in a significantly lower proportion of

250 s treated with five therapies: mycophenolate mofetil, rituximab, abatacept, nilotinib, and fresolimum

251 Monitored drugs were mycophenolate mofetil, sirolimus, or azathioprine.

252 FK), cyclosporine A (CSA), and mycophenolate mofetil/sodium (MMF).

253 tinue standard tacrolimus with mycophenolate mofetil (sTAC/MMF) and steroids.

254 nth posttransplant or continue mycophenolate mofetil + standard-exposure TAC (MMF + sTAC; n = 54) wit

255 crolimus starting on day 5 and mycophenolate mofetil starting on day 5 at 15 mg/kg three times daily

256 ine (starting at 2 mg/kg/d) or mycophenolate mofetil (starting at 2000 mg/d) after induction of remis

257 ged on a calcineurin inhibitor/mycophenolate mofetil/steroid-free immunosuppression.

258 ained on calcineurin inhibitor/mycophenolate mofetil/steroid-free regimen.

259 vo immunosuppressive treatment (mycofenolate mofetil, steroids, basiliximab) with delayed introductio

260 imab [Tac/Bas], 139 tacrolimus/mycophenolate mofetil [Tac/MMF], and 139 tacrolimus/MMF/steroids [trip

261 for 14 days with prednisolone, mycophenolate mofetil, tacrolimus, a combination of these 3 drugs, eve

262 ymocyte globulin induction and mycophenolate mofetil-tacrolimus maintenance immunosuppression were an

263 under anti-thymocyte globulin-mycophenolate mofetil-tacrolimus protocol.

264 rleukin 2 receptor blocker and mycophenolate mofetil/tacrolimus (Tac)/prednisone was employed.

265 was substituted with CBMPs and mycophenolate mofetil tapering was allowed.

266 udy (n = 370) and treated with mycophenolate mofetil (target dosage 3 gm/day) or intravenous cyclopho

267 ocked design to receive either mycophenolate mofetil (target dose 1500 mg twice daily) for 24 months

268 Fewer patients on mycophenolate mofetil than on cyclophosphamide prematurely withdrew fr

269 Combined prednisone and mycophenolate mofetil therapy is a potentially effective treatment for

270 Switching from mycophenolate mofetil to leflunomide successfully cleared verrucae vul

271 agiosum who were switched from mycophenolate mofetil to leflunomide.

272 It compared the addition of mycophenolate mofetil to steroids vs steroids/placebo to treat newly d

273 hate dehydrogenase inhibitors (mycophenolate mofetil) to the immunosuppressive armamentarium, replaci

274 fter each infusion); rapamycin+mycophenolate mofetil treatment as maintenance therapy.

275 Immunosuppressant mycophenolate mofetil treatment of enriched IL-17A(+) cells from MSC-p

276 ral methotrexate weekly or 1 g mycophenolate mofetil twice daily, with a corticosteroid taper.

277 lly, delaying cyclosporine and mycophenolate mofetil until after MTX administration did not seem to s

278 ted of ATG, anti-CD154mAb, and mycophenolate mofetil until age 8 to 12 months.

279 mia rates were associated with mycophenolate mofetil use (p < 0.0001) and EBV viral capsid antigen po

280 tem, stratified by concomitant mycophenolate mofetil use and presence or absence of interstitial pneu

281 ination at 3 months versus SRL+mycophenolate mofetil versus tacrolimus+mycophenolate mofetil de novo,

282 Mycophenolate mofetil was associated with PCP risk only in the RTR pop

283 Although mycophenolate mofetil was better tolerated and associated with less to

284 prophylaxis group, 15 mg/kg of mycophenolate mofetil was given orally three times daily from day 0 un

285 Mycophenolate mofetil was initiated postoperatively with delayed initi

286 Use of mycophenolate mofetil was inversely associated with vaccine response i

287 Among patients with AAV, mycophenolate mofetil was less effective than azathioprine for maintai

288 of a calcineurin inhibitor or mycophenolate mofetil was predictive for maintaining a DSA remission (

289 Mycophenolate mofetil was superior to azathioprine in maintaining a re

290 Mycophenolate mofetil was superior to azathioprine with respect to the

291 Mycophenolate mofetil was the treatment in 10 patients, and in 5 of th

292 ombination with tacrolimus and mycophenolate mofetil, was first demonstrated after nonmyeloablative c

293 lin induction, tacrolimus, and mycophenolate mofetil were also associated.

294 Tacrolimus and mycophenolate mofetil were required as well as either rabbit antithymo

295 ore transplant; tacrolimus and mycophenolate mofetil were started 1 week before surgery.

296 A calcineurin inhibitor and mycophenolate mofetil were used for postgrafting immunosuppression.

297 al tacrolimus, prednisone, and mycophenolate mofetil, which has continued until the present day (22 m

298 uppression with tacrolimus and mycophenolate mofetil with/without steroids.

299 on consisted of tacrolimus and mycophenolate mofetil without induction or depletional therapies.

300 esised that a 2 year course of mycophenolate mofetil would be safer, better tolerated, and produce lo